Genetic Insights: ADRB1 as a Potential Target for Clear Cell Renal Cell Carcinoma

752,817 and 315,137 individuals from Finnish GWAS cohorts were used in discovery and validation analyses to investigate the relationship between antihypertensive drug targets and clear cell renal cell carcinoma (CCRCC) risk. The dataset, authored by Honghui Zhu and last updated in June 2026, contains results from summary-data-based Mendelian randomization and colocalization analyses. It identifies ADRB1 and ADRB2 as targets associated with CCRCC risk and includes prognostic survival analysis findings.

Use Cases

• Validate genetic associations between drug targets and cancer risk based on Mendelian randomization results.
• Investigate the prognostic value of ADRB1 expression for tumor survival analysis in clear cell renal cell carcinoma.
• Perform meta-analysis on genetic risk factors using integrated results from two large cohorts.
• Explore colocalization evidence for shared genetic variation regions between drug targets and disease.

Strengths

• Analysis is based on large-scale GWAS data from over 750,000 individuals in the discovery cohort.
• Findings were externally validated using a separate cohort of over 315,000 individuals.
• Results include specific odds ratios and confidence intervals (e.g., ADRB1 OR: 1.100, 95% CI: 1.066–1.135).
• Colocalization analyses provide high posterior probability scores (e.g., ADRB1 PP4 = 0.996).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the Finnish cohort sources.

Provenance

Source

figshare, author Honghui Zhu.

Collection Method

Summary-data-based Mendelian randomization (SMR) and colocalization analyses performed on GWAS summary statistics.

Freshness

Last updated 2026-06-03 06:00:21; freshness should be verified.

Geography

Data derived from Finnish genetic cohorts.